Follow-up and surveillance after kidney cancer treatment — what the years afterwards actually involve

There is no single answer that fits everyone, and any page that gives you one is guessing. The interval is set from your risk band, which comes off the pathology report: the stage, the grade, the tumour type, whether it was removed completely and what the surgeon found around it. Scans sit closest together in the first period after treatment, when a return is most likely to show, and then move further apart as time passes without a problem. Your team writes the actual schedule using NCCN-based guidance, and you are entitled to have it in writing, with the dates and the reason for each test set out.

Long enough for the risk to have fallen, which means it varies. Low-risk tumours that were small, low grade and completely removed are followed for a defined period and then discharged or moved to a lighter routine. Higher-risk disease is followed for longer, because kidney cancer can occasionally return late, and the schedule reflects that rather than the calendar. Follow-up also does not stop being useful once the cancer checks ease off, since kidney function and blood pressure still need watching after part or all of a kidney has been removed. Ask your oncologist when your schedule is due to be reviewed and what would extend it.

No, and the two are often confused because both involve regular scans. Active surveillance means a small kidney tumour has been found and a decision has been taken to monitor it rather than treat it yet, so the scans are watching a tumour that is still there. Follow-up, or surveillance after treatment, happens once the cancer has been removed or treated, and the scans are checking that it has not come back and that the rest of your body and your remaining kidney are well. The schedules look similar on paper but they are answering completely different questions, and they are decided differently.

There is no blood marker that reliably detects returning kidney cancer, which surprises many people who expect something like a tumour-marker test. The blood work at follow-up is doing a different job. A full blood count looks for anaemia, kidney function tests including creatinine and estimated GFR track how the remaining kidney is coping, and calcium and liver tests are checked because abnormal results can point somewhere that needs a closer look. Blood pressure and a urine test for protein usually go with them. All of this blood work and monitoring is done in-house at CION alongside your consultation.

Do not save a new symptom for the next appointment. Tell your team about new or persistent bone pain, a cough or breathlessness that is not settling, blood in the urine, a new lump or swelling, unexplained weight loss, or fevers and night sweats that keep coming back. Most of the time these turn out to be something other than cancer, and that is exactly why they are worth checking rather than worrying about. If something does need attention, being seen early usually means more options. A scan can be brought forward between visits when there is a reason for it.

Yes, and it is a common reason people come to us. Bring the operation notes, the pathology report and the scans you already have. A CION medical oncologist reads them, works out the risk band from what the report actually says, and writes an NCCN-based follow-up schedule with the tests, the intervals and the review points set out. From there the consultations, the surveillance imaging, the blood and kidney-function monitoring and any systemic treatment are delivered in-house by our medical oncology team, while kidney surgery, ablation and PET-CT are coordinated with specialist urology, uro-oncology and interventional radiology partners, where they may also be billed.